Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of TJ003234 in Subjects With Severe Coronavirus Disease 2019 (COVID-19)

NCT04341116 is registered in ClinicalTrials.gov with I-Mab Biopharma US Limited as lead sponsor.

NCT NCT04341116
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04341116 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of TJ003234 in Subjects With Severe Coronavirus Disease 2019 (COVID-19)
Lead sponsor
I-Mab Biopharma US Limited
Phase
Phase 2/3
Overall status
Completed
Start date
April 11, 2020
Completion date
February 7, 2022
Enrollment
149 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus disease 2019 covid-19